[{"id":"52180f19-1459-4ab0-9689-e950c70f09df","acronym":"IMAGINE","url":"https://clinicaltrials.gov/study/NCT05138458","created_at":"2021-12-01T15:53:40.111Z","updated_at":"2024-07-02T16:35:29.495Z","phase":"Phase 1/2","brief_title":"A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL","source_id_and_acronym":"NCT05138458 - IMAGINE","lead_sponsor":"Myeloid Therapeutics","biomarkers":" ALK • CD5","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • MT-101"],"overall_status":"Suspended","enrollment":" Enrollment 40","initiation":"Initiation: 12/15/2021","start_date":" 12/15/2021","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-11-13"}]